Delafloxacin is a fluoroquinolone antibiotic used to treat skin and skin structure infections. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
- Mechanism
- Curator reviewed · 1 reference
Delafloxacin inhibits the activity of bacterial DNA topoisomerase IV and DNA gyrase (topoisomerase II). This interferes with bacterial DNA replication by preventing the relaxation of positive supercoils introduced as part of the elongation process. The resultant strain inhibits further elongation. Delafloxacin exerts concentration-dependent bacteriocidal activity.
- Primary indication
- Delafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group...Curator reviewed · 2 structured indications
- Formula / weight
- C18H12ClF3N4O4 · 440.76 g/mol (avg)
- First approval
- Canada, 2025 · United States, 2017 · European Union, 2020
- Code names
- ABT-492 · RX-3341 · WQ-3034
- Brand names
Resolves to
DYDCPNMLZGFQTM-UHFFFAOYSA-NSMILESNC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1FWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Delafloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account